The present invention relates to a pharmaceutical composition comprising: (I) at least one oxazole compound selected from the group consisting of 2,3-dihydro-6-nitroinidazo[2,l-b]oxazole compounds represented by general formula (1), optically active isomers thereof, and pharmacologically acceptable salts thereof general formula (1): wherein R1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer from 0 to 6,• and R2 represents any of the groups of general formula (A) to (F) below groups represented by general formula (A): wherein R3 represents any of the groups (1) to (6) such as herein described and (II) at least one cellulose compound selected from the group consisting of hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate, wherein the proportion of ingredient (II) to ingredient (I) in the pharmaceutical composition is 0.5 to 15 parts by weight per part by weight of ingredient (I).
